Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05521048 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Doxycycline in Cutaneous Schwannoma (NF2)

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 8, 2025 (before its estimated September 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Sep 2025 to Sep 1, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Dec 2025 to Dec 2026
    • Site details revised
    v7
  2. Primary completion date: Sep 2024 to Sep 2025
    • Study completion date: Dec 2024 to Dec 2025
    v6
  3. Primary completion date: Sep 2023 to Sep 2024v5
  4. Site contact updatedv4
  5. Start date changed from estimate of Sep 2022 to Sep 19, 2022v3
  6. Study description expanded, about 236 wordsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In this research study the investigators want to learn more about an alternate, local treatment for skin schwannomas. Specifically, local doxycycline intra-tumoral injection will be performed as a potential treatment for NF2-related skin schwannomas, ultimately reducing the risks and costs associated with standard surgical removal of such skin tumors if successful.
Trial Details
NCT Number NCT05521048
Lead Sponsor Massachusetts Eye and Ear Infirmary
Conditions
(from sponsor)		 Neurofibromatosis Type 2
Related terms Neurofibromatosis 2
Enrollment 19 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov